By Fineline Cube 
WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE’s innovative mRNA‑CAR technology with WestGene’s targeted lipid nanoparticle (tLNP) delivery platform to co‑advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene’s internationalization of its LNP/tLNP platform.
Deal Structure
| Item | Detail |
|---|---|
| Partners | WestGene Biopharma and CREATE Medicines, Inc. |
| Agreement Type | Strategic license and collaboration |
| Technologies | CREATE mRNA‑CAR technology + WestGene tLNP delivery platform |
| Programs | Three in vivo cell therapy candidates |
| Indications | Autoimmune diseases, hematologic malignancies, solid tumors |
| Date | 31 Aug 2026 |
Territorial Rights & Economics
| Component | Terms |
|---|---|
| WestGene Rights | Exclusive development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan |
| CREATE Rights | Exclusive development and commercialization globally outside Greater China |
| WestGene Economics | Early‑stage R&D funding, upfront payment, development and commercialization milestones, plus royalties on future product sales |
Technology Profile
- CREATE mRNA‑CAR Technology: Enables in vivo generation of CAR‑T cells, eliminating the need for ex vivo cell manufacturing
- WestGene tLNP Platform: Targeted lipid nanoparticle delivery system designed for cell‑type‑specific nucleic acid delivery
- Combined Value Proposition: A fully in vivo approach to cell therapy that could dramatically reduce cost, complexity, and turnaround time versus personalized ex vivo CAR‑T manufacturing
- Platform Positioning: The collaboration extends WestGene’s LNP/tLNP platform into international partnerships, reinforcing its licensing strategy
The agreement follows WestGene’s stated push to internationalize its delivery platform, pairing proprietary tLNP targeting with CREATE’s mRNA‑CAR engineering. For a modality historically constrained by bespoke manufacturing, in vivo cell therapy promises an off‑the‑shelf profile that could unlock broader patient access across autoimmune disease and oncology.
Market Impact & Outlook
- In Vivo Cell Therapy Momentum: The field has become one of biotech’s hottest frontiers, with major pharma striking deals to secure delivery capabilities
- Platform Validation: A cross‑border partnership validates WestGene’s tLNP technology as exportable intellectual property
- Strategic Logic: Greater China / ex‑China rights split aligns each partner with its strongest regional development and commercial infrastructure
- Competitive Positioning: In vivo CAR‑T approaches aim to undercut the cost and logistics of ex vivo therapies while expanding into chronic autoimmune indications
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the development, regulatory progress, and commercialization of collaboration products under the WestGene–CREATE agreement. Actual results may differ materially due to risks inherent in drug development, regulatory review, and competitive dynamics. Readers should not place undue reliance on such statements.-Fineline Info & Tech